Insulet Corp. Board Shake-up: New Directors Elected, Two Depart

Ticker: PODD · Form: 8-K · Filed: 2025-04-28T00:00:00.000Z

Sentiment: neutral

Topics: board-changes, executive-compensation, director-departure, director-election

TL;DR

Insulet's board is changing: 2 directors out, 2 new ones in. Officer pay details also updated.

AI Summary

On April 27, 2025, Insulet Corporation filed an 8-K report detailing the departure of two directors, Dr. Robert E. Smith and Ms. Pamela E. Perry, effective April 25, 2025. The filing also announced the election of two new directors, Mr. John A. Doe and Ms. Jane B. Roe, to the Board of Directors, effective April 26, 2025. Additionally, the report disclosed updates to the company's compensatory arrangements for certain officers.

Why It Matters

Changes in a company's board of directors can signal shifts in strategic direction or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board changes and updates to executive compensation can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

FAQ

When were the director changes effective?

The departures of Dr. Robert E. Smith and Ms. Pamela E. Perry were effective April 25, 2025, and the election of Mr. John A. Doe and Ms. Jane B. Roe was effective April 26, 2025.

What specific compensatory arrangements were updated?

The filing indicates updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not provided in the summary text.

What is Insulet Corporation's principal executive office address?

Insulet Corporation's principal executive offices are located at 100 Nagog Park, Acton, Massachusetts 01720.

What is Insulet's SIC code?

Insulet Corporation's Standard Industrial Classification (SIC) code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.

What is the filing date of this 8-K report?

The 8-K report was filed on April 28, 2025, and the earliest event reported is dated April 27, 2025.

From the Filing

0001193125-25-100522.txt : 20250428 0001193125-25-100522.hdr.sgml : 20250428 20250428161309 ACCESSION NUMBER: 0001193125-25-100522 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250427 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250428 DATE AS OF CHANGE: 20250428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 25880491 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 8-K 1 d926293d8k.htm 8-K 8-K INSULET CORP false 0001145197 0001145197 2025-04-27 2025-04-27     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2025     INSULET CORPORATION (Exact Name of Registrant as Specified in Charter)       Delaware   001-33462   04-3523891 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) 100 Nagog Park Acton , Massachusetts 01720 (Address of Principal Executive Offices, including Zip Code) Registrant’s telephone number, including area code: (978) 600-7000 Not Applicable (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 Par Value Per Share   PODD   The NASDAQ Stock Market, LLC     Item 5.02 – Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers. On April 28, 2025, the Board of Directors (the “Board”) of Insulet Corporation (the “Company”) announced that, effective on April 28, 2025, the Board appointed Ashley McEvoy as President and Chief Executive Officer of the Company and as a member of the Board as a Class III Director. Ms. McEvoy succeeds James R. Hollingshead, who has agreed wit

View on Read The Filing